Previous close | 0.8650 |
Open | 0.8600 |
Bid | 0.8805 x 200 |
Ask | 0.8906 x 200 |
Day's range | 0.8410 - 0.8897 |
52-week range | 0.7100 - 8.2000 |
Volume | |
Avg. volume | 1,486,808 |
Market cap | 54.073M |
Beta (5Y monthly) | 2.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | -6.8100 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.67 |
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. Conference & Webcast Details Date:May 15, 2024Time:8:00 a.m. to 8:25 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the B
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Som
Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype analysisDiagens will become an original equipment manufacturing (OEM